Unveiling the vasodilatory actions and mechanisms of relaxin
about
Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protectionG-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and preventionIn a Class of Their Own - RXFP1 and RXFP2 are Unique Members of the LGR FamilyCardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fractionRelaxin Treatment in an Ang-II-Based Transgenic Preeclamptic-Rat ModelSerelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actionsA vasoactive role for endogenous relaxin in mesenteric arteries of male mice.Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteinsAngiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humansRelaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide.Relaxin regulates vascular wall remodeling and passive mechanical properties in mice.Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.GPCRs as potential therapeutic targets in preeclampsia.Corpus luteal contribution to maternal pregnancy physiology and outcomes in assisted reproductive technologies.Relaxin treatment reverses insulin resistance in mice fed a high-fat dietThe emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.Recent advances in the understanding of the pathophysiology of preeclampsia.Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation.Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin)Serelaxin Treatment Reduces Oxidative Stress and Increases Aldehyde Dehydrogenase-2 to Attenuate Nitrate Tolerance.Vascular actions of relaxin: nitric oxide and beyond.Does serelaxin treatment alter passive mechanical wall properties in small resistance arteries?Diverse regulation of cardiac expression of relaxin receptor by α1- and β1-adrenoceptors.Ex vivo pharmacology of surgical samples of the uterosacral ligament. Part II: Effects of oxytocin and relaxin on arteries and vascular plexus.Effects of serelaxin on renal microcirculation in rats under control and high-angiotensin environments.RXFP1 Receptor Activation by Relaxin-2 Induces Vascular Relaxation in Mice a Gα-Protein/PI3Kß/γ/Nitric Oxide-Coupled Pathway
P2860
Q26740185-59F1E8D8-A11B-4CC9-8761-34AB8103770EQ26744192-41C67066-F6C5-4B0C-AD9A-1CC512C87244Q26781446-9720333A-C51E-4E77-BE5F-D21C8604808DQ26853363-25D60A27-38DE-4152-8351-F18B0C206795Q28550653-AC7CC7E3-87F5-4898-AFB8-80E8A1396088Q33970136-D082939A-26B3-4EFC-B439-3FE4BF1B60B8Q34226848-BB2EE719-10EA-421D-8D5C-9B7E1DF0DB03Q35039209-098C50C3-27A0-4349-A0F2-B9142680B5A2Q35042471-221B175F-60E3-4E80-981D-0D8757B3A9E4Q35046881-2B492B16-2BC8-4D43-8F94-DA9D4B96EB11Q35108756-CA677EBB-C2C0-453E-A34D-78D2CF2BE371Q35120364-FE1418B3-DE61-48C4-A6E2-38082EE253FAQ35383835-94851C4B-CCAE-44CB-8AFC-FC8A16F942D9Q36292811-9F68C4F9-4451-4FCD-8A0E-FC73C74216F6Q36380039-A3C31588-3477-4F32-8676-D29CDB551D8CQ36528009-AA3CD975-9394-45B9-AE80-5B84439C2DCDQ37110579-08F7989A-9BBE-4003-9D02-28E44247E725Q37147122-FB539D6F-392D-4371-B274-059F81237559Q37376964-387684F3-7DB4-46AF-A4FB-ADA6054A9A00Q37648577-2E027C7E-FACD-4CBA-BE2B-7E6560FCE927Q37686150-2744CE74-76BE-4446-8A00-522339E82147Q37712528-3491426C-398C-4A61-9D9D-E083C1D19B9EQ38945156-527A0366-CE4C-4B76-BEE5-84F5003CB4D5Q38960703-607C4BFB-A0E4-4F95-92B1-111332C0F1F4Q39188093-254BEC49-8164-461C-ABD5-48E610A8F778Q40039699-7C5B3922-D4B5-41EA-9934-0E7190003865Q47619900-267D36FF-FB42-4010-8207-B56061E0FE92Q58764679-3A3FD3BA-BD68-4E4D-B4CE-41DAD38CC1DB
P2860
Unveiling the vasodilatory actions and mechanisms of relaxin
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Unveiling the vasodilatory actions and mechanisms of relaxin
@ast
Unveiling the vasodilatory actions and mechanisms of relaxin
@en
type
label
Unveiling the vasodilatory actions and mechanisms of relaxin
@ast
Unveiling the vasodilatory actions and mechanisms of relaxin
@en
prefLabel
Unveiling the vasodilatory actions and mechanisms of relaxin
@ast
Unveiling the vasodilatory actions and mechanisms of relaxin
@en
P2860
P1433
P1476
Unveiling the vasodilatory actions and mechanisms of relaxin
@en
P2093
Kirk P Conrad
P2860
P356
10.1161/HYPERTENSIONAHA.109.133926
P407
P577
2010-05-24T00:00:00Z